ScholarWorks@중앙대학교

초록

Background: Effective postoperative pain management is challenging because of adverse effects associated with traditional analgesic methods. Multimodal analgesia, targeting multiple pain pathways, offers improved pain relief while reducing side effects. The authors evaluated the analgesic and anti-inflammatory effects of the ReproGel drug delivery system (DDS) combined with ropivacaine in a rat model of postoperative pain. Methods: Sixty-four Sprague–Dawley rats were randomly assigned to four groups: sham treatment, ReproGel DDS, ropivacaine 0.375%, and ReproGel DDS + ropivacaine 0.375%. Mechanical withdrawal threshold (MWT) tests and rotarod assessments were conducted at baseline; at 30, 60, 90, 120, 180, and 240 minutes; at 24 and 48 hours; and at 1 week postoperatively. Blood samples were collected at 24, 48 hours, and 1 week to measure levels of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 before euthanasia. Results: The ReproGel DDS + ropivacaine group demonstrated significantly higher MWT values, demonstrating enhanced analgesia from 30 to 240 minutes postoperatively. Combination treatment with ReproGel demonstrated superior effectiveness at 240 minutes, outperforming ropivacaine alone, indicating a sustained analgesic effect. IL-1β and IL-6 levels were significantly reduced in groups receiving ropivacaine, particularly in the ReproGel DDS + ropivacaine group, at 24 and 48 hours postoperatively. No motor impairment was observed, confirming the safety of ReproGel DDS + ropivacaine in preserving motor function. Conclusions: The combination of ReproGel DDS and ropivacaine 0.375% in a postoperative rat model offers prolonged analgesic and anti-inflammatory effects without motor impairment, positioning it as a safe and effective option for postoperative pain management.

키워드